New York, New York (PRWEB) November 14, 2013
As Risperdal lawsuit (http://www.therisperdallawsuit.com/) claims alleging use of the medication caused men and boys to develop gynecomastia, or male breasts, move forward in courts around the country, Bernstein Liebhard LLP notes that plaintiffs in the Risperdal litigation underway in Pennsylvania state court have filed a motion to enforce the settlement of dozens of claims over Risperdal and gynecomastia. According to the Motion, which was filed on November 5th in Philadelphia Court of Common Pleas, 77 plaintiffs in Risperdal lawsuits have asked Judge Arnold New to compel Johnson & Johnson to honor agreements it reached earlier this year to resolve their claims. Among other things, the Motion asserts that the Risperdal settlement agreements were reached on January 28, 2013. However, the motion asserts that Johnson & Johnson is now refusing to honor the agreement by arguing that the settlements should also extend to certain co-defendants. (Risperdal Litigation, case number 100300296)
“The developments in this proceeding are of great interest to our Firm, as we have heard from numerous individuals who, like the plaintiffs in these cases, are alleged victims of Risperdal and gynecomastia,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Risperdal lawsuit consultations to any individual who may have developed gynecomastia due to Risperdal.
According to court documents, the Risperdal lawsuits at issue in Philadelphia are among 250 claims pending in a consolidated litigation that were filed on behalf of alleged victims of gynecomastia and other Risperdal side effects. Among other things, those involving gynecomastia claim that Johnson & Johnson downplayed Risperdal’s association with male breast growth, and accuse the company of improperly marketing the drug for use in children.
The U.S. Department of Justice announced on November 4th that Johnson & Johnson had agreed to pay $2.2 billion to resolve criminal and civil charges that it improperly marketed certain medications, including Risperdal. Among other things, the government had accused Johnson & Johnson of misbranding Risperdal and promoting off-label use of the drug for children, elderly nursing home patients, and those with mental disabilities. A press release issued by the Justice Department noted that the drug was not approved for any pediatric uses until 2006, and the U.S. Food & Drug Administration (FDA) repeatedly warned the company against promoting the use of Risperdal in children.
Individuals who may have suffered male breast growth due to Risperdal could be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To learn more about the alleged association between Risperdal and gynecomastia, please visit Bernstein Liebhard LLP’s website. To arrange for a free Risperdal lawsuit review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com